Compare CMTL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | ICCC |
|---|---|---|
| Founded | 1967 | 1982 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 55.5M |
| IPO Year | 2024 | 1995 |
| Metric | CMTL | ICCC |
|---|---|---|
| Price | $5.28 | $6.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 296.0K | 13.2K |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $499,528,000.00 | $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.97 | N/A |
| P/E Ratio | ★ N/A | $32.00 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $1.19 | $4.32 |
| 52 Week High | $6.21 | $7.60 |
| Indicator | CMTL | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 53.42 |
| Support Level | $4.86 | $5.72 |
| Resistance Level | $6.15 | $6.91 |
| Average True Range (ATR) | 0.35 | 0.23 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 36.36 | 57.43 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.